These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32941420)

  • 1. CombiANT: Antibiotic interaction testing made easy.
    Fatsis-Kavalopoulos N; Roemhild R; Tang PC; Kreuger J; Andersson DI
    PLoS Biol; 2020 Sep; 18(9):e3000856. PubMed ID: 32941420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M
    J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.
    Thulin E; Thulin M; Andersson DI
    EBioMedicine; 2017 Sep; 23():111-118. PubMed ID: 28855073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4809-15. PubMed ID: 19704123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Hickman RA; Hughes D; Cars T; Malmberg C; Cars O
    Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance.
    Wambaugh MA; Shakya VPS; Lewis AJ; Mulvey MA; Brown JCS
    PLoS Biol; 2017 Jun; 15(6):e2001644. PubMed ID: 28632788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility testing of urinary isolates of Escherichia coli to mecillinam using NCCLS methodology.
    Skov R; Frimodt-Moller N; Menday P; Espersen F
    Int J Antimicrob Agents; 2005 Mar; 25(3):198-204. PubMed ID: 15737512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection.
    Oo TZ; Cole N; Garthwaite L; Willcox MD; Zhu H
    J Antimicrob Chemother; 2010 Jun; 65(6):1243-51. PubMed ID: 20375033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
    J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
    Chojnacki M; Philbrick A; Wucher B; Reed JN; Tomaras A; Dunman PM; Wozniak RAF
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30420484
    [No Abstract]   [Full Text] [Related]  

  • 14. [Do different interpretative methods used for evaluation of checkerboard synergy test affect the results?].
    Ozseven AG; Sesli Çetin E; Ozseven L
    Mikrobiyol Bul; 2012 Jul; 46(3):410-20. PubMed ID: 22951653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin.
    Karlowsky JA; Thornsberry C; Jones ME; Sahm DF
    Clin Infect Dis; 2003 Jan; 36(2):183-7. PubMed ID: 12522750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.
    Chojnacki M; Philbrick A; Scherzi T; Pecora N; Dunman PM; Wozniak RAF
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of other antimicrobial drugs is associated with trimethoprim resistance in patients with urinary tract infections caused by E. coli.
    Mulder M; Verbon A; Lous J; Goessens W; Stricker BH
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2283-2290. PubMed ID: 31494829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
    BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
    D'Souza BB; Padmaraj SR; Rekha PD; Tellis RC; Prabhu S; Pothen P
    Microb Drug Resist; 2014 Dec; 20(6):550-4. PubMed ID: 25055029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of fluoroquinolone-resistant Escherichia coli in urinary tract infections.
    Shigemura K; Arakawa S; Miura T; Nakano Y; Tanaka K; Fujisawa M
    Jpn J Infect Dis; 2008 May; 61(3):226-8. PubMed ID: 18503177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.